摘要
微小RNA(micro RNA,mi RNA)是一类长度约为22个核苷酸的小分子内源性非编码RNA,其主要通过与靶标基因m RNA的3′非编码区的完全或不完全配对,降解靶标基因m RNA或抑制其翻译,从而参与调控细胞发育、分化、增殖、凋亡等活动。mi RNA可通过调控其靶标基因参与的信号通路,影响肿瘤的发生和发展,发挥类似于癌基因或抑癌基因的功能。弥漫大B细胞淋巴瘤(DLBCL)是最常见的一类非霍奇金淋巴瘤,其临床表现、形态学、免疫表型及遗传学特征具有高度异质性。本文综述了近年来mi RNA在DLBCL发病机制中作用的研究进展,包括mi RNA的作用靶点、信号通路及其在临床分期、分型、预后评估、治疗策略中的应用价值。
MicroRNA(miRNA)is short endogenous non-coding RNAs with the length of 22 nt,it regulates the expression of target genes by binding to the 3′UTR of mRNA and inducing either miRNA degradation or translational repression.Researchers have found that miRNA regulate a wide range of biological processes,including cell development,differentiation,proliferation and apoptosis.miRNA performs its tumor suppressor or oncogenic function by regulating the expression of target genes and correspondingly regulating the signaling pathways.Diffuse large B cell lymphoma(DLBCL),the most common B-cell non-Hodgkin lymphoma,is a kind of diseases with an extremely heterogeneity in the clinical manifestation,morphology,immunophenotype,and genetic characteristics.In this review,we summarized the target and signaling pathway of miRNA in the pathogenesis of diffuse large B cell lymphoma in recent years,and its application value in clinical staging,typing,prognosis evaluation and treatment strategies.
作者
阚育田
张翼鷟
赵海丰
KAN Yu-tian;Zhang Yi-zhuo;Zhao Hai-feng(Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin Clinical Research Center for Cancer,Tianjin 300060,China)
出处
《天津医药》
CAS
北大核心
2018年第4期436-439,共4页
Tianjin Medical Journal
基金
国家自然科学基金资助项目(81570201,81100337,81470283)
